Grace Therapeutics (GRCE)
NASDAQ:GRCE
GRCE Stock Chart & Stats
$4.63
-$0.02(-0.47%)
At close: 4:00 PM EST
$4.63
-$0.02(-0.47%)
Day’s Range― - ―
52-Week Range$1.75 - $4.94
Previous CloseN/A
Volume30.96K
Average Volume (3M)58.56K
Market Cap
$71.64M
Enterprise Value$46.74M
Total Cash (Recent Filing)$18.67M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Jun 23, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding15,474,026
10 Day Avg. Volume55,886
30 Day Avg. Volume58,559
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.36K
Enterprise Value/Ebitda-6.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$9.19M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthZero reported debt and a multi‑million dollar equity cushion materially reduce refinancing and interest risks for a pre‑commercial biotech. This durable capital structure supports ongoing R&D and clinical programs, extending runway and providing strategic optionality over the next several quarters.
Focused Specialty Therapy ModelA clear focus on niche formulations and delivery approaches targets specialized patient populations where differentiation and clinical benefit can command premium pricing and limited direct competition. That strategic specialization supports durable competitive positioning and clearer go‑to‑market pathways once clinical proof is achieved.
Improving Operating LossesA multi‑period reduction in net loss indicates tightening expense discipline and more efficient program spend. This trend, if sustained, lowers future financing needs, improves runway visibility, and signals management’s ability to control costs during clinical development phases over the next several quarters.
Bears Say
Pre‑revenue OperationsNo commercial revenue means the company remains fully dependent on external capital to fund R&D and operations. Absent near‑term product commercialization, this structural reliance elevates dilution and financing execution risk and leaves long‑term viability contingent on clinical milestones or successful funding rounds.
Persistent Negative Cash FlowSustained negative operating and free cash flow signals ongoing cash burn that must be covered by financing. Volatility and sharply negative FCF growth reduce runway predictability and raise the likelihood of future equity raises, which can dilute shareholders and constrain strategic flexibility over the medium term.
Eroding Equity And Negative ReturnsMaterial declines in equity combined with negative ROE indicate the company has been consuming capital without generating shareholder returns. This structural erosion reduces balance sheet resilience, heightens the risk of future dilution or constrained financing terms, and weakens long‑term capital efficiency.
Grace Therapeutics News
GRCE FAQ
What was Grace Therapeutics’s price range in the past 12 months?
Grace Therapeutics lowest stock price was $1.75 and its highest was $4.94 in the past 12 months.
What is Grace Therapeutics’s market cap?
Grace Therapeutics’s market cap is $71.64M.
When is Grace Therapeutics’s upcoming earnings report date?
Grace Therapeutics’s upcoming earnings report date is Jun 23, 2026 which is in 82 days.
How were Grace Therapeutics’s earnings last quarter?
Grace Therapeutics released its earnings results on Feb 12, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.14.
Is Grace Therapeutics overvalued?
According to Wall Street analysts Grace Therapeutics’s price is currently Overvalued.
Does Grace Therapeutics pay dividends?
Grace Therapeutics does not currently pay dividends.
What is Grace Therapeutics’s EPS estimate?
Grace Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does Grace Therapeutics have?
Grace Therapeutics has 15,474,026 shares outstanding.
What happened to Grace Therapeutics’s price movement after its last earnings report?
Grace Therapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went down -1.671%.
Which hedge fund is a major shareholder of Grace Therapeutics?
Currently, no hedge funds are holding shares in GRCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grace Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 25.2%
Last 30 Days ▲ 25.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.10%
12-Months-Change
Fundamentals
Return on Equity
-10.61%
Trailing 12-Months
Asset Growth
11.86%
Trailing 12-Months
Company Description
Grace Therapeutics
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
GRCE Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
8.48%
Insiders
2.72% Mutual Funds
17.63% Other Institutional Investors
68.59% Public Companies and
Individual Investors